Aducanumab – which Biogen is developing with Japanese drugmaker Eisai – was all but abandoned in 2019 after the partners decided that two phase 3 trials of the drug were unlikely to show an ...

1 Cardiac Intensive Care Unit, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China 2 Department of Neurology, The First Affiliated Hospital of Guangxi Medical ...

I'm Marc Goodman, one of the biopharma analyst, and we're lucky to have Biogen with us here, Alisha Alaimo, who is the President of North America. Thank you very much for joining us. Well ...

Yes, Piller's argument includes the case of FDA's controversial decision to grant Biogen's Alzheimer's drug aducanumab (Aduhelm) accelerated approval. That approval was a mistake, but government ...

A small Swiss biotech has ter­mi­nat­ed a mid-stage test of a new type of oral drug for peo­ple with Alzheimer’s dis­ease, ac­cord­ing to the fed­er­al … ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has reaffirmed its positive opinion by consensus for ...

This list is current as of: 2025-02-28. An Excel version of the updated SUR List is available from the Overview page.

For Biogen, an expensive gamble has paid off, as even with accelerated approval the company stands to make billions of dollars from aducanumab, given it estimates there are around 1.5 million ...

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months. The following table summarizes their recent ...

Biogen Inc.’s stock BIIB tumbled 7% Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged behind consensus, as sales of its multiple sclerosis drug ...